Short answer
Disc Medicine, Inc. (IRON) filed an 8-K current report with the SEC on February 27, 2026 reporting Item 2.05 (Costs Associated with Exit or Disposal Activities). FDA issued complete response letter (CRL) Feb 13 for bitopertin NDA (EPP/XLP), triggering commercial strategy pivot and layoffs.
Disc Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.05 · Costs Associated with Exit or Disposal Activities
- FDA issued complete response letter (CRL) Feb 13 for bitopertin NDA (EPP/XLP), triggering commercial strategy pivot and layoffs
- Workforce cut ~20%, targeting commercial and supporting functions: signals company abandoning near-term commercial launch plans
- Restructuring charge ~$2.0M, primarily severance, recognized mostly in Q1 2026
- Plan completion targeted Q2 2026; CRL outcome raises uncertainty around bitopertin's regulatory path and timeline to any revenue
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Disc Medicine, Inc. 8-K filings
Get the next IRON 8-K as it lands
Follow IRON for push alerts, or ask the research agent what this filing means.